Research on tumor immunotherapy has made tremendous progress in the past decades,
with numerous studies entering the clinical evaluation. The cancer vaccine is considered a …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive
and deadliest cancer worldwide, with an overall survival (OS) rate, all stages combined, of …

In pancreatic ductal adenocarcinoma (PDAC) patients, we show that response to radiation
therapy (RT) is characterized by increased IL-2Rβ and IL-2Rγ along with decreased IL-2Rα …

Cancer is a major burden on the healthcare system, and new therapies are needed.
Recently, the development of immunotherapies, which aim to boost or use the immune …

Purpose: Metastasis remains a major hurdle in treating aggressive malignancies such as
pancreatic ductal adenocarcinoma (PDAC). Improving response to treatment, therefore …

Dendritic cells (DCs) are efficient antigen-presenting cells (APCs) and potent activators of
naïve T cells. Therefore, they act as a connective ring between innate and adaptive …

Cold tumor immune microenvironment (TIME) of pancreatic cancer (PC) with minimal
dendritic cell (DC) and T cell infiltration can result in insufficient immunotherapy and …

Conventional vaccines are widely used to boost human natural ability to defend against
foreign invaders, such as bacteria and viruses. Recently, therapeutic cancer vaccines …

Every type of cancer tissue is theoretically more vulnerable to viral infection. This natural
proclivity has been harnessed as a new anti-cancer therapy by employing oncolytic viruses …

Pancreatic cancer is one of the most challenging cancer types in clinical treatment
worldwide. This study aimed to understand the tumorigenesis mechanism and explore …